Nanoparticle Vaccines Encompassing the Respiratory Syncytial Virus (RSV) G Protein CX3C Chemokine Motif Induce Robust Immunity Protecting from Challenge and Disease

The Respiratory Syncytial Virus G Protein Conserved Domain Induces a Persistent and Protective Antibody Response in Rodents

(2012) Thien N. Nguyen et al.   PLoS One

Immunogenicity and Protective Capacity of a Virosomal Respiratory Syncytial Virus Vaccine Adjuvanted with Monophosphoryl Lipid A in Mice

(2012) Tobias Kamphuis et al.   PLoS One

Antibody response to the central unglycosylated region of the respiratory syncytial virus attachment protein in mice

(2012) Yoshihiko Murata et al.   VACCINE

Viruslike Particle Vaccine Induces Protection Against Respiratory Syncytial Virus Infection in Mice

(2011) Fu-Shi Quan et al.   JOURNAL OF INFECTIOUS DISEASES

Assembly and Immunological Properties of Newcastle Disease Virus-Like Particles Containing the Respiratory Syncytial Virus F and G Proteins

(2010) L. W. McGinnes et al.   JOURNAL OF VIROLOGY

Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis

(2010) Harish Nair et al.   LANCET

Lipopeptide-adjuvanted respiratory syncytial virus virosomes: A safe and immunogenic non-replicating vaccine formulation

(2010) Toon Stegmann et al.   VACCINE

Synthetic nanoparticle vaccines produced by layer-by-layer assembly of artificial biofilms induce potent protective T-cell and antibody responses in vivo

(2010) Thomas J. Powell et al.   VACCINE

Conserved cysteine residues within the attachment G glycoprotein of respiratory syncytial virus play a critical role in the enhancement of cytotoxic T-lymphocyte responses

(2010) Guillermina A. Melendi et al.   VIRUS GENES

The host response and molecular pathogenesis associated with respiratory syncytial virus infection

(2009) Christine M Oshansky et al.   Future Microbiology

Therapeutic Monoclonal Antibody Treatment Targeting Respiratory Syncytial Virus (RSV) G Protein Mediates Viral Clearance and Reduces the Pathogenesis of RSV Infection in BALB/c Mice

(2009) Lia M. Haynes et al.   JOURNAL OF INFECTIOUS DISEASES

Newcastle Disease Virus-Like Particles Containing Respiratory Syncytial Virus G Protein Induced Protection in BALB/c Mice, with No Evidence of Immunopathology

(2009) M. R. Murawski et al.   JOURNAL OF VIROLOGY

Vaccination To Induce Antibodies Blocking the CX3C-CX3CR1 Interaction of Respiratory Syncytial Virus G Protein Reduces Pulmonary Inflammation and Virus Replication in Mice

(2009) W. Zhang et al.   JOURNAL OF VIROLOGY

The Burden of Respiratory Syncytial Virus Infection in Young Children

(2009) Caroline Breese Hall et al.   NEW ENGLAND JOURNAL OF MEDICINE

Respiratory syncytial virus subunit vaccine based on a recombinant fusion protein expressed transiently in mammalian cells

(2009) Sophie Nallet et al.   VACCINE

The effect of poly(d,l-lactide-co-glycolide) microparticles with polyelectrolyte self-assembled multilayer surfaces on the cross-presentation of exogenous antigens

(2008) Ya-Wun Yang et al.   BIOMATERIALS

Human Genetic Factors and Respiratory Syncytial Virus Disease Severity

(2008) I. Miyairi et al.   CLINICAL MICROBIOLOGY REVIEWS

New strategies for control of respiratory syncytial virus infection

(2008) James D Nokes et al.   CURRENT OPINION IN INFECTIOUS DISEASES

Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus

(2008) Matthew R Olson et al.   Expert Review of Vaccines

Host immunity during RSV pathogenesis

(2008) Susan M. Bueno et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Pulmonary eosinophilia requires interleukin-5, eotaxin-1, and CD4+ T cells in mice immunized with respiratory syncytial virus G glycoprotein

(2008) Teresa R. Johnson et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Sub-Nucleocapsid Nanoparticles: A Nasal Vaccine against Respiratory Syncytial Virus

(2008) Xavier Roux et al.   PLoS One

Pre-Clinical Evaluation of a Novel Nanoemulsion-Based Hepatitis B Mucosal Vaccine

(2008) Paul E. Makidon et al.   PLoS One

Protective T cell immunity against respiratory syncytial virus is efficiently induced by recombinant BCG

(2008) S. M. Bueno et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Respiratory syncytial virus (RSV) vaccines—Two steps back for one leap forward

(2007) Ultan F. Power   JOURNAL OF CLINICAL VIROLOGY